FOR IMMEDIATE RELEASE
NEW YORK, N.Y. – December 20, 2007 – Medidata Solutions, a global provider of electronic clinical data capture (EDC), management and reporting solutions, today announced that PAREXEL International, a leading global biopharmaceutical services organization, has joined Medidata’s ASPire to Win™ program, a non-exclusive application service provider (ASP) partnership and business model. Through this program, Medidata will provide tools and training to enable PAREXEL to implement Medidata Rave® as an EDC solution for its global client base.
“PAREXEL has provided EDC-driven solutions for our clients’ clinical development programs for more than a decade. EDC is now a key component of a total eClinical solution that we believe will help the biopharmaceutical industry realize greater improvements in efficiency and data quality in clinical studies,” said Mark A. Goldberg, M.D., President of Clinical Research Services and Perceptive Informatics at PAREXEL. “Medidata’s EDC solution has demonstrated increasing traction in the marketplace with our client base, across all phases of clinical research. This program will further strengthen our knowledge of Medidata Rave technology and our ability to incorporate it as appropriate into clinical studies.”
PAREXEL decided to formalize its relationship with Medidata by joining the ASPire to Win program. The program enables PAREXEL to globally manage clinical trials using Medidata Rave. PAREXEL’s selection of Medidata Rave was driven by the product’s broad user acceptance, easy and fast deployment capability and key features including real-time access to clinical data.
“We are excited to see PAREXEL take advantage of our ASPire to Win program, which continues to expand with the industry’s increased adoption of Medidata Rave,” said Tarek Sherif, CEO of Medidata Solutions. “With this alliance, PAREXEL will be able to help its clients conduct clinical trials more efficiently. In addition, our clients will have access to PAREXEL’s in-depth expertise in clinical development, experience conducting thousands of studies and access to a wide array of geographical locations in which to conduct clinical research.”
About PAREXEL International
PAREXEL International is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 64 locations throughout 51 countries around the world, and has approximately 7,000 employees. For more information about PAREXEL International visit www.PAREXEL.com.
About Medidata Solutions Worldwide
Medidata Solutions helps the world’s leading pharmaceutical, biotechnology, medical device and research organizations maximize the value of their clinical research investments. Innovative process design, technology and services streamline clinical trials by providing early visibility to reliable clinical data—the lifeblood of every research organization. Working with companies and institutions both large and small, Medidata Solutions helps clinical researchers safely accelerate the process of bringing life-enhancing treatments to market—on six continents and in more than 80 countries. Medidata Solutions brings significant value to its broad client base with deep clinical experience and expertise in more than 20 therapeutic areas, projects in Phase I, II, III, IV, registries and surveillance, and studies with thousands of investigators and tens-of-thousands of subjects. For more information, please visit www.mdsol.com.
Contact:
Susan Lombardo
Lois Paul & Partners
781.782.5767
Susan_Lombardo@lpp.com